Switch theme
Sign up to access all valuation multiples
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
2018
70
LTM Revenue $10.4M
LTM EBITDA n/a
-$20.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aligos Therapeutics has a last 12-month revenue of $10.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Aligos Therapeutics achieved revenue of $3.9M and an EBITDA of -$86.5M.
Aligos Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aligos Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $15.5M | $3.9M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$85.1M | -$86.5M | XXX | XXX | XXX |
| EBITDA Margin | -548% | -2193% | XXX | XXX | XXX |
| Net Profit | -$96.0M | -$87.7M | XXX | XXX | XXX |
| Net Margin | -618% | -2223% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Aligos Therapeutics's stock price is $5.
Aligos Therapeutics has current market cap of $28.2M, and EV of -$20.4M.
See Aligos Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$20.4M | $28.2M | XXX | XXX | XXX | XXX | $-17.41 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Aligos Therapeutics has market cap of $28.2M and EV of -$20.4M.
Aligos Therapeutics's trades at -2.0x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Aligos Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Aligos Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$20.4M | XXX | XXX | XXX |
| EV/Revenue | -5.2x | XXX | XXX | XXX |
| EV/EBITDA | 0.2x | XXX | XXX | XXX |
| P/E | -0.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAligos Therapeutics's NTM/LTM revenue growth is 86%
Aligos Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Aligos Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Aligos Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Aligos Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -75% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -2193% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -2107% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 579% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1781% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2360% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aligos Therapeutics acquired XXX companies to date.
Last acquisition by Aligos Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Aligos Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Aligos Therapeutics founded? | Aligos Therapeutics was founded in 2018. |
| Where is Aligos Therapeutics headquartered? | Aligos Therapeutics is headquartered in United States of America. |
| How many employees does Aligos Therapeutics have? | As of today, Aligos Therapeutics has 70 employees. |
| Who is the CEO of Aligos Therapeutics? | Aligos Therapeutics's CEO is Dr. Lawrence M. Blatt,PhD. |
| Is Aligos Therapeutics publicy listed? | Yes, Aligos Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Aligos Therapeutics? | Aligos Therapeutics trades under ALGS ticker. |
| When did Aligos Therapeutics go public? | Aligos Therapeutics went public in 2020. |
| Who are competitors of Aligos Therapeutics? | Similar companies to Aligos Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Aligos Therapeutics? | Aligos Therapeutics's current market cap is $28.2M |
| What is the current revenue of Aligos Therapeutics? | Aligos Therapeutics's last 12-month revenue is $10.4M. |
| What is the current EV/Revenue multiple of Aligos Therapeutics? | Current revenue multiple of Aligos Therapeutics is -2.0x. |
| What is the current revenue growth of Aligos Therapeutics? | Aligos Therapeutics revenue growth between 2023 and 2024 was -75%. |
| Is Aligos Therapeutics profitable? | Yes, Aligos Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
